BACKGROUND AND AIMS: Dysbiosis of the gut microbiota is a well-known correlate of the pathogenesis of inflammatory bowel disease [IBD]. However, few studies have examined the microbiome in very early-onset [VEO] IBD, which is defined as onset of IBD before 6 years of age. Here we focus on the viral portion of the microbiome-the virome-to assess possible viral associations with disease processes, reasoning that any viruses potentially associated with IBD might grow more robustly in younger subjects, and so be more detectable. METHODS: Virus-like particles [VLPs] were purified from stool samples collected from patients with VEO-IBD [n = 54] and healthy controls [n = 23], and characterized by DNA and RNA sequencing and VLP particle counts. RESULTS: The total number of VLPs was not significantly different between VEO-IBD and healthy controls. For bacterial viruses, the VEO-IBD subjects were found to have a higher ratio of Caudovirales vs to Microviridae compared to healthy controls. An increase in Caudovirales was also associated with immunosuppressive therapy. For viruses infecting human cells, Anelloviridae showed higher prevalence in VEO-IBD compared to healthy controls. Within the VEO-IBD group, higher levels of Anelloviridae DNA were also positively associated with immunosuppressive treatment. To search for new viruses, short sequences enriched in VEO-IBD samples were identified, and some could be validated in an independent cohort, although none was clearly viral; this provides sequence tags to interrogate in future studies. CONCLUSIONS: These data thus document perturbations to normal viral populations associated with VEO-IBD, and provide a biomarker-Anelloviridae DNA levels-potentially useful for reporting the effectiveness of immunosuppression.
BACKGROUND AND AIMS: Dysbiosis of the gut microbiota is a well-known correlate of the pathogenesis of inflammatory bowel disease [IBD]. However, few studies have examined the microbiome in very early-onset [VEO] IBD, which is defined as onset of IBD before 6 years of age. Here we focus on the viral portion of the microbiome-the virome-to assess possible viral associations with disease processes, reasoning that any viruses potentially associated with IBD might grow more robustly in younger subjects, and so be more detectable. METHODS: Virus-like particles [VLPs] were purified from stool samples collected from patients with VEO-IBD [n = 54] and healthy controls [n = 23], and characterized by DNA and RNA sequencing and VLP particle counts. RESULTS: The total number of VLPs was not significantly different between VEO-IBD and healthy controls. For bacterial viruses, the VEO-IBD subjects were found to have a higher ratio of Caudovirales vs to Microviridae compared to healthy controls. An increase in Caudovirales was also associated with immunosuppressive therapy. For viruses infecting human cells, Anelloviridae showed higher prevalence in VEO-IBD compared to healthy controls. Within the VEO-IBD group, higher levels of Anelloviridae DNA were also positively associated with immunosuppressive treatment. To search for new viruses, short sequences enriched in VEO-IBD samples were identified, and some could be validated in an independent cohort, although none was clearly viral; this provides sequence tags to interrogate in future studies. CONCLUSIONS: These data thus document perturbations to normal viral populations associated with VEO-IBD, and provide a biomarker-Anelloviridae DNA levels-potentially useful for reporting the effectiveness of immunosuppression.
Authors: James D Lewis; Eric Z Chen; Robert N Baldassano; Anthony R Otley; Anne M Griffiths; Dale Lee; Kyle Bittinger; Aubrey Bailey; Elliot S Friedman; Christian Hoffmann; Lindsey Albenberg; Rohini Sinha; Charlene Compher; Erin Gilroy; Lisa Nessel; Amy Grant; Christel Chehoud; Hongzhe Li; Gary D Wu; Frederic D Bushman Journal: Cell Host Microbe Date: 2015-10-14 Impact factor: 21.023
Authors: Marijana Basic; Lydia M Keubler; Manuela Buettner; Marcel Achard; Gerhard Breves; Bernd Schröder; Anna Smoczek; Anne Jörns; Dirk Wedekind; Nils H Zschemisch; Claudia Günther; Detlef Neumann; Stefan Lienenklaus; Siegfried Weiss; Mathias W Hornef; Michael Mähler; André Bleich Journal: Inflamm Bowel Dis Date: 2014-03 Impact factor: 5.325
Authors: Jason M Norman; Scott A Handley; Megan T Baldridge; Lindsay Droit; Catherine Y Liu; Brian C Keller; Amal Kambal; Cynthia L Monaco; Guoyan Zhao; Phillip Fleshner; Thaddeus S Stappenbeck; Dermot P B McGovern; Ali Keshavarzian; Ece A Mutlu; Jenny Sauk; Dirk Gevers; Ramnik J Xavier; David Wang; Miles Parkes; Herbert W Virgin Journal: Cell Date: 2015-01-22 Impact factor: 41.582
Authors: Arie Levine; Anne Griffiths; James Markowitz; David C Wilson; Dan Turner; Richard K Russell; John Fell; Frank M Ruemmele; Thomas Walters; Mary Sherlock; Marla Dubinsky; Jeffrey S Hyams Journal: Inflamm Bowel Dis Date: 2010-11-08 Impact factor: 5.325
Authors: Hailiang Huang; Ming Fang; Luke Jostins; Maša Umićević Mirkov; Gabrielle Boucher; Carl A Anderson; Vibeke Andersen; Isabelle Cleynen; Adrian Cortes; François Crins; Mauro D'Amato; Valérie Deffontaine; Julia Dmitrieva; Elisa Docampo; Mahmoud Elansary; Kyle Kai-How Farh; Andre Franke; Ann-Stephan Gori; Philippe Goyette; Jonas Halfvarson; Talin Haritunians; Jo Knight; Ian C Lawrance; Charlie W Lees; Edouard Louis; Rob Mariman; Theo Meuwissen; Myriam Mni; Yukihide Momozawa; Miles Parkes; Sarah L Spain; Emilie Théâtre; Gosia Trynka; Jack Satsangi; Suzanne van Sommeren; Severine Vermeire; Ramnik J Xavier; Rinse K Weersma; Richard H Duerr; Christopher G Mathew; John D Rioux; Dermot P B McGovern; Judy H Cho; Michel Georges; Mark J Daly; Jeffrey C Barrett Journal: Nature Date: 2017-06-28 Impact factor: 49.962
Authors: Eric I Benchimol; Charles N Bernstein; Alain Bitton; Matthew W Carroll; Harminder Singh; Anthony R Otley; Maria Vutcovici; Wael El-Matary; Geoffrey C Nguyen; Anne M Griffiths; David R Mack; Kevan Jacobson; Nassim Mojaverian; Divine Tanyingoh; Yunsong Cui; Zoann J Nugent; Janie Coulombe; Laura E Targownik; Jennifer L Jones; Desmond Leddin; Sanjay K Murthy; Gilaad G Kaplan Journal: Am J Gastroenterol Date: 2017-04-18 Impact factor: 10.864
Authors: Tao Zuo; Xiao-Juan Lu; Yu Zhang; Chun Pan Cheung; Siu Lam; Fen Zhang; Whitney Tang; Jessica Y L Ching; Risheng Zhao; Paul K S Chan; Joseph J Y Sung; Jun Yu; Francis K L Chan; Qian Cao; Jian-Qiu Sheng; Siew C Ng Journal: Gut Date: 2019-03-06 Impact factor: 23.059
Authors: Caitlin W Elgarten; Ceylan Tanes; Jung-Jin Lee; Lara A Danziger-Isakov; Michael S Grimley; Michael Green; Marian G Michaels; Jessie L Barnum; Monica I Ardura; Jeffery J Auletta; Jesse Blumenstock; Alix E Seif; Kyle L Bittinger; Brian T Fisher Journal: Pediatr Blood Cancer Date: 2021-10-28 Impact factor: 3.167
Authors: Fatemeh Adiliaghdam; Hajera Amatullah; Sreehaas Digumarthi; Tahnee L Saunders; Raza-Ur Rahman; Lai Ping Wong; Ruslan Sadreyev; Lindsay Droit; Jean Paquette; Philippe Goyette; John D Rioux; Richard Hodin; Kathie A Mihindukulasuriya; Scott A Handley; Kate L Jeffrey Journal: Sci Immunol Date: 2022-04-08